Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
Abstract Epithelial cell adhesion molecule (EpCAM), a tumor antigen for antibody–drug conjugates (ADCs), is highly expressed in many epithelial cancers. However, the clinical progress of EpCAM ADCs has been challenging, primarily due to their toxicity in normal high-expression tissues such as the ga...
| Published in: | Experimental Hematology & Oncology |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00624-9 |